Literature DB >> 25092746

BRCA2 mutation linked to lung cancer risk.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25092746     DOI： 10.1158/2159-8290.CD-NB2014-096

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  1 in total

1.  Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.

Authors:  Jing Luo; Xinchi Dai; Hua Hu; Jie Chen; Lujun Zhao; Changyong Yang; Jifeng Sun; Lianmin Zhang; Qian Wang; Shilei Xu; Yue Xu; Ningbo Liu; Guoguang Ying; Ping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-30       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.